Orexigen Therapeutics Inc. (OREX) Hits New 1-Year Low at $3.18
Shares of Orexigen Therapeutics Inc. (NASDAQ:OREX) hit a new 52-week low during trading on Tuesday . The company traded as low as $3.18 and last traded at $3.19, with a volume of 105,997 shares changing hands. The stock had previously closed at $3.38.
Separately, Zacks Investment Research raised shares of Orexigen Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 21st. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $2.61.
The stock has a 50 day moving average price of $4.12 and a 200 day moving average price of $7.39. The stock’s market capitalization is $47.82 million.
Orexigen Therapeutics (NASDAQ:OREX) last announced its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.02. The firm earned $5 million during the quarter, compared to analysts’ expectations of $7.78 million. The company’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.14) EPS. Equities analysts anticipate that Orexigen Therapeutics Inc. will post ($5.61) EPS for the current year.
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.